Celebrex may prevent cancer but raises heart risks

Celebrex, a treatment for arthritis, may help prevent colon cancer in high-risk patients, but it also raises the risk of heart attack and stroke, researchers said on Monday.

Pfizer Inc. said sustained, higher doses of Celebrex can reduce pre-cancerous polyps by as much as 45 percent, based on the drug’s overall performance in two clinical trials.

However, a broad analysis of both studies found patients taking Celebrex had more cardiovascular events, contradicting a preliminary analysis of one of the studies.

Celebrex, a so-called COX-2 inhibitor, belongs to the same class of drugs as Merck & Co. Inc.’s Vioxx, which Merck pulled from the market in 2004 after a study showed it doubled the risk of heart attack and stroke.

The studies, presented on Monday at the annual meeting of the American Association for Cancer Research, evaluated whether the over-expression of the COX-2 enzyme is related to the growth and spread of colorectal tumors.

COX-2 inhibitors may reduce the occurrence of the precursor, colorectal adenomas (benign tumors), in patients with a family history of the disease, as well as the development of sporadic colorectal tumors.

Both trials enrolled patients who had already had precancerous colon polyps removed. They were about 60 years old, on average, at the start of the trial; most had cardiovascular risk factors such as High Blood Pressure, diabetes, chest pain, previous heart attacks, strokes or were smokers.

One study, the APC trial, was co-sponsored by the National Cancer Institute and Pfizer. The other, the PreSAP trial, was sponsored by Pfizer.

Final results of the APC trial confirmed preliminary results from the study released in late 2004 showing a statistically significant increase in the risk of serious cardiovascular events in the Celebrex group compared to patients taking a dummy pill.

Pfizer said preliminary results of the PreSAP trial did not show an increase of cardiovascular events. But Pfizer said a new, broader analysis of cardiovascular events, including chest pain, found more cardiovascular events with Celebrex compared to placebo.

Pfizer said the results are consistent with the current warnings on cardiovascular risk in the Celebrex label.

The drugmaker said it has provided available information about the APC and PreSAP trials to regulatory agencies around the world. Pfizer said it will submit final study reports to the U.S. Food and Drug Administration and other regulatory agencies.

RELATED STORIES:
Obesity hurts recovery after colon cancer surgery   Lifestyle Changes Would Lead to Sharp Drop in Colorectal Cancers   Genetic Differences Point to Ethnic and Racial Disparities in Colorectal Cancer Risk   Studies lend insights into colorectal cancer screening   Surgery Not Necessary for Most Late-Stage Colorectal Cancers   Statins don’t protect against cancer: study   Regular Screenings and Healthy Living Reduce Colon Cancer Risk   Western and Japanese diets up colon cancer risk   The first map of colon cancer in Spain is published   Increase in P53 Mutation Linked to Advanced Colorectal Cancer in Blacks   Celecoxib May Help Prevent Colorectal Cancer In High Risk Patients   Colon cancer risk in women does not seem to be reduced by physical activity   Colorectal Cancer Awareness Month Resources from the AGA   New treatments offer better survival and fresh challenges in colorectal cancer   African-Americans with colorectal cancer have poorer outcomes, lower survival rates   Colorectal Cancer in Vietnamese Americans   Language a Barrier to Colorectal Cancer Screening in Mexican-Americans   Obesity linked to poor colon cancer prognosis   Hormone replacement tied to lower colon cancer risk   Simple, personalized interventions improve colorectal cancer screening rates   Smoking Related to Subset of Colorectal Cancers with Absent DNA Repair Proteins   Discovery of a novel mechanism for the development of colon cancer

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]